Reata Pharmaceuticals, Inc.(RETA) Stock Research - Grey Stern Research

Reata Pharmaceuticals, Inc. (RETA) Stock Analysis

$172.36 (0.02%)

RETA Financial Performance


Use the table below to view Reata Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2023

Metric Value Ranking among Peers
Price $172.36 -
52 Week Low $21.83 -
52 Week High $172.46 -
Market Cap $6.6 Billion 2/11
Gross Margin 96% 4/11
Profit Margin 100% 1/11
EBITDA margin -356% 9/11
Q2 - 2023 Revenue $22.7 Million 7/11
Q2 - 2023 Earnings $193.0 Million 2/11
Q2 - 2023 Free Cash Flow -$70.2 Million 8/11
Trailing 4 Quarters Revenue $24.4 Million 9/11
Trailing 4 Quarters Earnings -$82.3 Million 5/11
Quarterly Earnings Growth 362% 2/11
Annual Earnings Growth 72% 4/11
Quarterly Revenue Growth 2885% 2/11
Annual Revenue Growth 596% 2/11
Cash On Hand $48.8 Million 11/11
Short Term Debt $2.5 Million 5/11
Long Term Debt $163.5 Million 4/11

Reata Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Reata Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 4/11
PS 269.17 1/11
PB 75.22 1/11
PC 134.44 1/11
Liabilities to Equity 4.76 1/11
ROA -0.16 6/11
ROE -0.94 11/11
Current Ratio 1.21 10/11
Quick Ratio 0.80 9/11
Long Term Debt to Equity 1.87 2/11
Debt to Equity 1.90 2/11
Burn Rate -0.26 9/11
Cash to Cap 0.01 10/11
CCR -0.36 9/11
EV to EBITDA -82.50 10/11
EV to Revenue 273.97 1/11

Company Details

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

CEO: Mr. J. Warren Huff

Website: https://www.reatapharma.com

Address: 5320 Legacy Dr Plano, TEXAS

Exchange: NASDAQ Global Market

Industry: Biotechnology

Reata Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Reata Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $3.9 Billion
Sarepta Therapeutics, Inc. SRPT $11.4 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Madrigal Pharmaceuticals, Inc. MDGL $6.0 Billion
PTC Therapeutics, Inc. PTCT $3.3 Billion
Krystal Biotech, Inc. KRYS $4.2 Billion
Vir Biotechnology, Inc. VIR $1.4 Billion
CureVac N.V. CVAC $912.9 Million
Terns Pharmaceuticals, Inc. TERN $393.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RETA Income Statements
Quarter Year Revenue Earnings
Q2 2023 $ 22.7 Million $193.0 Million
Q1 2023 $ 195,000 -$110.8 Million
Q4 2022 $ 914,000 -$85.5 Million
Q3 2022 $ 540,000 -$79.0 Million
Q2 2022 $ 762,000 -$73.6 Million
Q1 2022 $ 914,000 -$73.8 Million
Q4 2021 $ 933,000 -$85.4 Million
Q3 2021 $ 7.4 Million -$71.8 Million

View All

RETA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2023 $48.8 Million $502.6 Million $166.0 Million $87.3 Million
Q1 2023 $84.9 Million $453.6 Million $117.9 Million -$1.7 Billion
Q4 2022 $42.3 Million $514.5 Million $119.5 Million -$65.7 Million
Q3 2022 $31.9 Million $583.6 Million $140.7 Million $4.5 Million
Q2 2022 $147.2 Million $631.5 Million $142.5 Million $68.6 Million
Q1 2022 $532.0 Million $679.9 Million $141.6 Million $127.8 Million
Q4 2021 $590.3 Million $735.0 Million $136.0 Million $186.0 Million
Q3 2021 $713.2 Million $731.8 Million $0 $256.0 Million

View All

RETA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2023 -$70.2 Million -$274,000 -$36.1 Million
Q1 2023 -$81.6 Million -$141,000 $42.6 Million
Q4 2022 -$50.8 Million -$367,000 $10.4 Million
Q3 2022 -$156.7 Million -$2.9 Million -$115.2 Million
Q2 2022 -$51.4 Million -$2.3 Million -$384.8 Million
Q1 2022 -$58.5 Million -$288,000 -$58.3 Million
Q4 2021 -$123.1 Million -$193,000 -$123.0 Million
Q3 2021 -$42.8 Million -$674,000 -$42.5 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions